Logo - International Journal of Pharmaceutical Compounding

Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles

Author(s):  Voudrie Mark A, Alexander Bridget, Allen D Brett

Issue:  May/Jun 2011 - Volume 15, Number 3
View All Articles in Issue

Abstract:  Verapamil hydrochloride is widely prescribed to treat multiple cardiovascular diseases. There are a number of generic manufacturers of verapamil tablets and injectables. The need for other administration options for patients who cannot take tablets has led compounding pharmacies to seek other alternatives, namely, oral solutions and suspensions. The stability of these compounded verapamil oral liquid preparations is a concern to anyone making them. The objective of this study was to determine the stability of verapamil hydrochloride in SyrSpend SF in comparison to stability of verapamil hydrochloride in Ora-Sweet SF:Ora-Plus (1:1). The two samples were compounded in 50-mL batches and stored in amber 60-mL plastic prescription bottles at United States Pharmacopeia refrigerated conditions. Five replicates at each pre-defined time point were assayed by a stability-indicating high performance liquid chromatographic method with an end date of 60 days. No degradation peaks were seen in the chromatograms for either preparation at any time point and the recovery of verapamil hydrochloride was within 90% to 110% of the initial concentration for all replicates. Verapamil hydrochloride is stable in amber plastic prescription bottles for 60 days when refrigerated for both SyrSpend SF and Ora-Sweet SF:Ora-Plus (1:1).

Related Keywords: Mark A. Voudrie II, MS, PMP, Bridget Alexander, BS, CAPM, D. Brett Allen, BS, verapamil hydrochloride, calcium channel blocker, oral suspensions, syrups, suspending vehicles, stability


Purchase this article for download in electronic PDF format from IJPC at for $35 at:

Search the entire IJPC archive by keyword, topic, or issue at: